Discover the Latest Advances in Treating Diabetic Foot Infections
The advances in medical treatment have opened new doors, especially for complex conditions such as diabetic foot osteomyelitis (DFO). Recent studies have demonstrated how local antibiotic delivery with innovative solutions can significantly reduce post-surgical infection complications. One noteworthy research endeavor is the BIG D-FOOT study, which explored the use of STIMULAN® in the management of DFO.
A Breakthrough in Infection Management
STIMULAN® serves as a pioneering absorbable calcium matrix designed for use in conjunction with antibiotics. This approach showcases tremendous promise, especially in reducing the recurrence of infections after surgery. The findings from the BIG D-FOOT study indicate that employing antibiotic-loaded STIMULAN® has led to significant improvements in patient outcomes.
Key Findings from BIG D-FOOT Study
The BIG D-FOOT study, a double-blind, randomized controlled trial, has produced compelling evidence regarding the efficacy of STIMULAN®. The key outcomes revealed that:
- The use of STIMULAN® showed significant superiority compared to a placebo in preventing infective complications.
- The study was concluded ahead of schedule due to overwhelmingly positive results.
- Patients who initially received the placebo, but later switched to STIMULAN® with antibiotics, achieved full healing within two months.
- Cost analysis demonstrated that this method is economically sustainable when compared to traditional treatment options.
These impressive results solidify the potential of STIMULAN® in tackling the complex challenges posed by infections in diabetic patients.
Highlights of the Upcoming Symposium at EBJIS
Biocomposites, a leader in medical devices for infection management, will feature prominently at the upcoming EBJIS Annual Meeting. Their symposium, titled 'From diabetic foot osteomyelitis to peri-prosthetic joint infection: what are the most appropriate treatment strategies?', will dive into innovative techniques for dealing with such infections.
Meet the Speakers and Moderators
The session will be moderated by esteemed professionals in the field, Dr. Massimiliano De Paolis and Professor Pierluigi Viale. Key figures, including Dr. Matteo Monami, the lead author of the BIG D-FOOT study, will share their insights, enhancing collaboration among medical experts.
Future Directions in Infection Management
The symposium aims to deliver breakthrough insights regarding local antibiotic delivery systems within complex patient demographics. With local administration becoming a focal point, participants will review the efficiency and effectiveness of various new strategies.
About Biocomposites
Based in Keele, Biocomposites specializes in creating advanced products for infection control in bone and soft tissue. Their operational reach extends globally, targeting diverse markets including Europe, Asia, and the Americas. The innovative solutions provided by Biocomposites have made considerable impacts in over a million procedures every year.
Join Us for Insightful Discussions
The EBJIS Annual Meeting serves as a hub for sharing essential knowledge about treating musculoskeletal infections. Attendees can expect a wealth of information from selective discussions revolving around best practices and emerging methodologies.
Frequently Asked Questions
What is the BIG D-FOOT study?
The BIG D-FOOT study is a pivotal research initiative exploring the effectiveness of local antibiotic delivery through STIMULAN® in treating diabetic foot osteomyelitis.
What are the main findings of the study?
The study found significant advantages of using STIMULAN® over traditional treatments, including reduced infection rates and faster patient healing.
Who will be speaking at the symposium?
Keynote speakers include Dr. Matteo Monami, Dr. Massimiliano De Paolis, and Professor Pierluigi Viale, among others who are leaders in healthcare and infectious diseases.
Where will the symposium be held?
The symposium is set to take place at the Room Sala Italia, Bologna Congress Centre during the EBJIS Annual Meeting.
Why is STIMULAN® significant in treatment?
STIMULAN® is recognized for its unique properties of supporting localized antibiotic delivery, which significantly enhances treatment outcomes in complex infections like DFO.
